Leukotriene B4 and C4 in cerebrospinal fluid from children with meningitis and febrile seizures.
Target: Rights to the
leukotriene C4 synthase inhibitor programme (OX-CLI project)
INV104 (zafirlukast) is a
leukotriene receptor antagonist (LTRA) that reduces inflammation, constriction of the airways, and the build-up of mucus in the lungs.
Taken orally, zileuton inhibits the 5-LO enzyme, which would otherwise catalyze the formation of
leukotrienes from arachidonic acid.
Omega-6 fatty acids are commonly thought to be pro-inflammatory, because linoleic acid (the major omega-3 fatty acid in the diet) is converted in part to arachidonic acid, which is a precursor for pro-inflammatory eicosanoids such as prostaglandin E2,
leukotriene B4, and thromboxane A2.
Akari is a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically for the treatment of rare and orphan diseases, in particular those where the complement (C5) or
leukotriene (LTB4) systems, or both complement and
leukotrienes together, play a primary role in disease progression.
Montelukast inhibits the actions of
leukotriene D4 (LTD4) by reversibly binding on the cysteinyl
leukotriene receptor CysLT1 in the lungs and bronchial tubes.
Akari's lead drug candidate, Coversin, is a C5 complement inhibitor that also independently and specifically inhibits
leukotriene B4 (LTB4) activity.
It is demonstrated that montelukast, a cysteinyl
leukotriene receptor 1 antagonist, alleviates WAS-induced bladder damage by inhibiting mast cell activation and preserve the urothelial mucous layer through its antioxidant effects.
When the animals were 12 months old, the equivalent of age 60 in humans, they were treated with zileuton, a drug that inhibits
leukotriene formation by blocking the 5-lipoxygenase enzyme.
Akari is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by the dysregulation of complement C5 and/or
leukotriene B4 (LTB4).